Dietary Rhythms and MASLD-Related Hepatocellular Carcinoma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Oct 26

PMID 39456575

Authors

Nadia Malakmahmoudi

Roberta Pisu

Ezio Laconi

Fabio Marongiu

Affiliations

Soon will be listed here.

Abstract

Dietary rhythms have emerged as a relevant variable in the equation relating nutrition and health. Both experimental and epidemiological studies point to potential beneficial effects of adequate fasting intervals between meals on the evolution of chronic diseases associated with aging. Metabolic dysfunction-associated steatotic liver disease (MASLD) is eminently related to diet and unsurprisingly, diet-based approaches are a mainstay in countering its long-term clinical evolution, including the emergence of hepatocellular carcinoma (HCC). We briefly discuss current evidence linking fasting intervals, MASLD, and HCC and propose a working hypothesis to reconcile some of the apparently conflicting results. This hypothesis relates the beneficial effects of time-restricted eating schedules to the quantity and quality of food, and it is easily amenable to testing.

References

Marjot T, Tomlinson J, Hodson L, Ray D . Timing of energy intake and the therapeutic potential of intermittent fasting and time-restricted eating in NAFLD. Gut. 2023; 72(8):1607-1619. PMC: 10359613. DOI: 10.1136/gutjnl-2023-329998. View

Cai H, Qin Y, Shi Z, Chen J, Zeng M, Zhou W . Effects of alternate-day fasting on body weight and dyslipidaemia in patients with non-alcoholic fatty liver disease: a randomised controlled trial. BMC Gastroenterol. 2019; 19(1):219. PMC: 6921505. DOI: 10.1186/s12876-019-1132-8. View

Hyun J, Al Abo M, Dutta R, Oh S, Xiang K, Zhou X . Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease. J Hepatol. 2021; 75(3):623-633. PMC: 8380690. DOI: 10.1016/j.jhep.2021.04.033. View

Polyzos S, Kountouras J, Mantzoros C . Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism. 2018; 92:82-97. DOI: 10.1016/j.metabol.2018.11.014. View

Jiang L, Shan J, Shen J, Wang Y, Yan P, Liu L . Androgen/androgen receptor axis maintains and promotes cancer cell stemness through direct activation of Nanog transcription in hepatocellular carcinoma. Oncotarget. 2016; 7(24):36814-36828. PMC: 5095041. DOI: 10.18632/oncotarget.9192. View

Johnston P, Sen M, Hua Y, Camarco D, Shun T, Lazo J . High Content Imaging Assays for IL-6-Induced STAT3 Pathway Activation in Head and Neck Cancer Cell Lines. Methods Mol Biol. 2017; 1683:229-244. PMC: 6507410. DOI: 10.1007/978-1-4939-7357-6_14. View

Koutoukidis D, Astbury N, Tudor K, Morris E, Henry J, Noreik M . Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. JAMA Intern Med. 2019; 179(9):1262-1271. PMC: 6604126. DOI: 10.1001/jamainternmed.2019.2248. View

Sato T, Oishi K . Time-restricted feeding has a limited effect on hepatic lipid accumulation, inflammation and fibrosis in a choline-deficient high-fat diet-induced murine NASH model. PLoS One. 2024; 19(1):e0296950. PMC: 10824409. DOI: 10.1371/journal.pone.0296950. View

VanSaun M, Mendonsa A, Gorden D . Hepatocellular proliferation correlates with inflammatory cell and cytokine changes in a murine model of nonalchoholic fatty liver disease. PLoS One. 2013; 8(9):e73054. PMC: 3767686. DOI: 10.1371/journal.pone.0073054. View

10.

McGlynn K, London W . The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis. 2011; 15(2):223-43, vii-x. PMC: 4141529. DOI: 10.1016/j.cld.2011.03.006. View

11.

Miyakoshi M, Yamamoto M, Tanaka H, Ogawa K . Serine 727 phosphorylation of STAT3: an early change in mouse hepatocarcinogenesis induced by neonatal treatment with diethylnitrosamine. Mol Carcinog. 2012; 53(1):67-76. DOI: 10.1002/mc.21949. View

12.

Eslam M, Valenti L, Romeo S . Genetics and epigenetics of NAFLD and NASH: Clinical impact. J Hepatol. 2017; 68(2):268-279. DOI: 10.1016/j.jhep.2017.09.003. View

13.

Polyzos S, Chrysavgis L, Vachliotis I, Chartampilas E, Cholongitas E . Nonalcoholic fatty liver disease and hepatocellular carcinoma:Insights in epidemiology, pathogenesis, imaging, prevention and therapy. Semin Cancer Biol. 2023; 93:20-35. DOI: 10.1016/j.semcancer.2023.04.010. View

14.

Bea S, Jeong H, Filion K, Yu O, Cho Y, Lee B . Outcomes of SGLT-2i and GLP-1RA Therapy Among Patients With Type 2 Diabetes and Varying NAFLD Status. JAMA Netw Open. 2023; 6(12):e2349856. PMC: 10755620. DOI: 10.1001/jamanetworkopen.2023.49856. View

15.

Xia J, Guo W, Hu M, Jin X, Zhang S, Liu B . Resynchronized rhythmic oscillations of gut microbiota drive time-restricted feeding induced nonalcoholic steatohepatitis alleviation. Gut Microbes. 2023; 15(1):2221450. PMC: 10266122. DOI: 10.1080/19490976.2023.2221450. View

16.

Sadria M, Layton A . Aging affects circadian clock and metabolism and modulates timing of medication. iScience. 2021; 24(4):102245. PMC: 7995490. DOI: 10.1016/j.isci.2021.102245. View

17.

Hatori M, Vollmers C, Zarrinpar A, DiTacchio L, Bushong E, Gill S . Time-restricted feeding without reducing caloric intake prevents metabolic diseases in mice fed a high-fat diet. Cell Metab. 2012; 15(6):848-60. PMC: 3491655. DOI: 10.1016/j.cmet.2012.04.019. View

18.

Lin W, Karin M . A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007; 117(5):1175-83. PMC: 1857251. DOI: 10.1172/JCI31537. View

19.

Sakurai T, He G, Matsuzawa A, Yu G, Maeda S, Hardiman G . Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell. 2008; 14(2):156-65. PMC: 2707922. DOI: 10.1016/j.ccr.2008.06.016. View

20.

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View